RVL Pharmaceuticals plc (RVLPQ)
USD 0.0
(900.0%)
USD 0.0
(900.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 77.41 Million USD | 13.95% |
| 2021 | 67.93 Million USD | -75.48% |
| 2020 | 277.09 Million USD | -20.5% |
| 2019 | 348.54 Million USD | -21.37% |
| 2018 | 443.29 Million USD | -8.4% |
| 2017 | 483.95 Million USD | -5.72% |
| 2016 | 513.29 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 71.1 Million USD | -8.15% |
| 2023 Q2 | 69.07 Million USD | -2.85% |
| 2022 Q3 | 86.8 Million USD | 30.9% |
| 2022 Q2 | 66.31 Million USD | -11.37% |
| 2022 FY | 77.41 Million USD | 13.95% |
| 2022 Q1 | 74.82 Million USD | -4.77% |
| 2022 Q4 | 77.41 Million USD | -10.82% |
| 2021 Q4 | 78.57 Million USD | 43.39% |
| 2021 FY | 67.93 Million USD | -75.48% |
| 2021 Q3 | 54.79 Million USD | 0.0% |
| 2020 FY | 277.09 Million USD | -20.5% |
| 2019 FY | 348.54 Million USD | -21.37% |
| 2018 FY | 443.29 Million USD | -8.4% |
| 2017 FY | 483.95 Million USD | -5.72% |
| 2016 FY | 513.29 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -282103.915% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -717.85% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -6.825% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -9471.906% |
| Rebus Holdings, Inc. | 5.24 Million USD | -1376.86% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -31.184% |
| Qrons Inc. | 1.48 Million USD | -5100.264% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -6213.503% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -3.333% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -173107.893% |
| Skye Bioscience, Inc. | 14.07 Million USD | -450.14% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -45.234% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -707.94% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -18264.06% |
| SQZ Biotechnologies Company | 50.03 Million USD | -54.713% |
| Intellipharmaceutics International Inc. | 12 Million USD | -544.671% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -1910.088% |
| Mesoblast Limited | 188.44 Million USD | 58.918% |
| Marizyme, Inc. | 26.67 Million USD | -190.215% |
| Genus plc | 485 Million USD | 84.038% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -1225.039% |
| Pharming Group N.V. | 244.07 Million USD | 68.281% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -3751.343% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -2976.586% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1937.289% |
| ContraFect Corporation | 32.53 Million USD | -137.979% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -3807.368% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -1922.574% |
| IMV Inc. | 37.93 Million USD | -104.09% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -557.291% |
| MultiCell Technologies, Inc. | 1617.67 USD | -4785610.312% |
| ONE Bio Corp. | 27.49 Million USD | -181.559% |
| Accustem Sciences Inc. | 1.07 Million USD | -7073.295% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -3560.259% |
| Q BioMed Inc. | 8.13 Million USD | -851.895% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 6.653% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -1404.401% |
| Biomind Labs Inc. | 1.49 Million USD | -5065.914% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 34.791% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -756.175% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -320.666% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -5299.198% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -54382.564% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -38393.705% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -1247.362% |
| GB Sciences, Inc. | 5.41 Million USD | -1329.002% |
| Alpha Cognition Inc. | 7.16 Million USD | -980.523% |
| HST Global, Inc. | 593.59 Thousand USD | -12942.101% |
| CSL Limited | 18.62 Billion USD | 99.584% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -6048.144% |
| Halberd Corporation | 728.71 Thousand USD | -10523.711% |
| Enzolytics Inc. | 365.26 Million USD | 78.805% |
| Agentix Corp. | 2.51 Million USD | -2983.661% |
| Resverlogix Corp. | 67.39 Million USD | -14.869% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -9130.243% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 82.601% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -4416.744% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -212.846% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -550.394% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -2012.238% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1838.456% |
| Zenith Capital Corp. | 27.56 Thousand USD | -280711.781% |
| Genscript Biotech Corporation | 1.32 Billion USD | 94.161% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -32339.012% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -1973.13% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -11270.907% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -2754.987% |
| Kadimastem Ltd | 3.5 Million USD | -2108.843% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -115570.337% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -54.021% |
| BioStem Technologies, Inc. | 15.9 Million USD | -386.756% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -16559.601% |
| LadRx Corporation | 2.2 Million USD | -3418.11% |
| Cell Source, Inc. | 15.8 Million USD | -389.773% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1318.513% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1318.513% |
| NovAccess Global Inc. | 7.86 Million USD | -884.857% |
| Affymax, Inc. | 8.87 Million USD | -772.698% |
| Itoco Inc. | 1.65 Million USD | -4582.996% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -3673.558% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -1179.831% |
| Mobile Lads Corp. | 1.31 Million USD | -5793.961% |
| CytoDyn Inc. | 127.89 Million USD | 39.468% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -185112.565% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -4842.424% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -600.905% |
| SYBLEU INC | 681.41 Thousand USD | -11261.245% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1168.735% |
| International Stem Cell Corporation | 5.27 Million USD | -1367.065% |
| Bioxytran, Inc. | 3.24 Million USD | -2282.428% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -12270.707% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -1576.736% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -88.84% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -247.707% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -3722.331% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -1313.235% |
| Neutra Corp. | 973.52 Thousand USD | -7852.203% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -166.817% |
| PureTech Health plc | 125.58 Million USD | 38.354% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1960.538% |
| IXICO plc | 1.9 Million USD | -3973.953% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -277.11% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 25.074% |
| CSL Limited | 18.62 Billion USD | 99.584% |
| Cellectis S.A. | 249.36 Million USD | 68.955% |